BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Pu Y, Yang JH, Yang J. Progress in treatment of primary biliary cirrhosis. Shijie Huaren Xiaohua Zazhi 2014; 22(34): 5273-5278 [DOI: 10.11569/wcjd.v22.i34.5273] [Reference Citation Analysis]
2 Djurisic S, Rath A, Gaber S, Garattini S, Bertele V, Ngwabyt SN, Hivert V, Neugebauer EAM, Laville M, Hiesmayr M, Demotes-Mainard J, Kubiak C, Jakobsen JC, Gluud C. Barriers to the conduct of randomised clinical trials within all disease areas. Trials 2017;18:360. [PMID: 28764809 DOI: 10.1186/s13063-017-2099-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
3 John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. Am J Gastroenterol 2021;116:1913-23. [PMID: 33989225 DOI: 10.14309/ajg.0000000000001280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dyakova L, Culita DC, Marinescu G, Alexandrov M, Kalfin R, Patron L, Alexandrova R. Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents. Biotechnol Biotechnol Equip 2014;28:543-51. [PMID: 26019542 DOI: 10.1080/13102818.2014.927973] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM. NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatol Commun. 2018;2:1037-1050. [PMID: 30202819 DOI: 10.1002/hep4.1209] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 12.5] [Reference Citation Analysis]
6 Chang JC, Beuers U, Oude Elferink RP. The Emerging Role of Soluble Adenylyl Cyclase in Primary Biliary Cholangitis. Dig Dis 2017;35:217-23. [PMID: 28249274 DOI: 10.1159/000450914] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, Bacon B, Luketic V, Vuppalanchi R, Medendorp S, Dorenbaum A, Kennedy C, Novak P, Gu J, Apostol G, Hirschfield GM. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatol Commun 2019;3:365-81. [PMID: 30859149 DOI: 10.1002/hep4.1305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
8 Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D. Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011648. [PMID: 28350426 DOI: 10.1002/14651858.CD011648.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
9 Marchioni Beery RM, Vaziri H, Forouhar F. Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. J Clin Transl Hepatol 2014;2:266-84. [PMID: 26357630 DOI: 10.14218/JCTH.2014.00024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
10 Zhao P, Liu WW, Li JF, Wang CY, Wang H, Xu J, Wang RF, Yang HZ, Jin C, Wei ZM. Predictors of liver failure in primary biliary cirrhosis. Ups J Med Sci. 2015;120:47-51. [PMID: 25430562 DOI: 10.3109/03009734.2014.985763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
11 Parés A. Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? Clin Liver Dis (Hoboken) 2014;3:29-33. [PMID: 31236266 DOI: 10.1002/cld.311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Boerlage TCC, Haal S, Maurits de Brauw L, Acherman YIZ, Bruin S, van de Laar AWJM, Moes DE, van Wagensveld BA, de Vries CEE, van Veen R, Schouten R, Dijkgraaf MG, Fockens P, Gerdes VEA, Voermans RP. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial). BMC Gastroenterol 2017;17:164. [PMID: 29262795 DOI: 10.1186/s12876-017-0674-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
13 Khanna A, Hegade VS, Jones DE. Management of Fatigue in Primary Biliary Cholangitis. Curr Hepatology Rep 2019;18:127-33. [DOI: 10.1007/s11901-019-00458-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Strassburg CP. [Modern treatment of primary biliary cholangitis]. Internist (Berl) 2018;59:105-12. [PMID: 29110023 DOI: 10.1007/s00108-017-0347-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Watt M, Spence JC, Tandon P. Development of a Theoretically Informed Web-Based Mind-Body Wellness Intervention for Patients With Primary Biliary Cholangitis: Formative Study. JMIR Form Res 2021;5:e29064. [PMID: 34623317 DOI: 10.2196/29064] [Reference Citation Analysis]
16 Zhu GQ, Shi KQ, Huang S, Huang GQ, Lin YQ, Zhou ZR, Braddock M, Chen YP, Zheng MH. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine (Baltimore) 2015;94:e609. [PMID: 25789951 DOI: 10.1097/MD.0000000000000609] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
17 Verhaag EM, Buist-Homan M, Koehorst M, Groen AK, Moshage H, Faber KN. Hormesis in Cholestatic Liver Disease; Preconditioning with Low Bile Acid Concentrations Protects against Bile Acid-Induced Toxicity. PLoS One 2016;11:e0149782. [PMID: 26950211 DOI: 10.1371/journal.pone.0149782] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
18 Kennedy L, Francis H, Invernizzi P, Venter J, Wu N, Carbone M, Gershwin ME, Bernuzzi F, Franchitto A, Alvaro D, Marzioni M, Onori P, Gaudio E, Sybenga A, Fabris L, Meng F, Glaser S, Alpini G. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. FASEB J 2019;33:10269-79. [PMID: 31251081 DOI: 10.1096/fj.201802606R] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
19 Li Y, Lu LG. Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases. J Clin Transl Hepatol 2018;6:425-30. [PMID: 30637221 DOI: 10.14218/JCTH.2018.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
20 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 124] [Cited by in F6Publishing: 91] [Article Influence: 31.0] [Reference Citation Analysis]
21 Simental-Mendía M, Sánchez-García A, Simental-Mendía LE. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol 2020;86:1476-88. [PMID: 32285958 DOI: 10.1111/bcp.14311] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol 2015; 7(7): 926-941 [PMID: 25954476 DOI: 10.4254/wjh.v7.i7.926] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
23 Trzos K, Pydyn N, Jura J, Kotlinowski J. Selected transgenic murine models of human autoimmune liver diseases. Pharmacol Rep 2022. [PMID: 35032321 DOI: 10.1007/s43440-021-00351-y] [Reference Citation Analysis]
24 Mago S, Wu GY. Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review. J Clin Transl Hepatol 2020;8:336-46. [PMID: 33083257 DOI: 10.14218/JCTH.2020.00036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Robles-Díaz M, Nezic L, Vujic-Aleksic V, Björnsson ES. Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review. Front Pharmacol 2021;12:744488. [PMID: 34776963 DOI: 10.3389/fphar.2021.744488] [Reference Citation Analysis]
26 Sánchez-Salgado JC, Estrada-Soto S, García-Jiménez S, Montes S, Gómez-Zamudio J, Villalobos-Molina R. Analysis of Flavonoids Bioactivity for Cholestatic Liver Disease: Systematic Literature Search and Experimental Approaches. Biomolecules 2019;9:E102. [PMID: 30875780 DOI: 10.3390/biom9030102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Parrish RH, Ashworth LD, Löbenberg R, Benavides S, Cies JJ, Macarthur RB. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics 2022;14:1032. [DOI: 10.3390/pharmaceutics14051032] [Reference Citation Analysis]
28 Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther 2015;9:5407-19. [PMID: 26491252 DOI: 10.2147/DDDT.S92041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
29 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
30 Kouroumalis E, Notas G. Primary biliary cirrhosis: From bench to bedside. World J Gastrointest Pharmacol Ther 2015; 6(3): 32-58 [PMID: 26261733 DOI: 10.4292/wjgpt.v6.i3.32] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
31 Javaid A, Poongkunran M, Allard FD, Kyaw W, Maung HH, Lau D. Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report. Gastroenterol Rep (Oxf). 2016; Epub ahead of print. [PMID: 26893441 DOI: 10.1093/gastro/gov064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Mai ZH, Huang Y, Huang D, Huang ZS, He ZX, Li PL, Zhang S, Weng JF, Gu WL. Reversine and herbal Xiang-Sha-Liu-Jun-Zi decoction ameliorate thioacetamide-induced hepatic injury by regulating the RelA/NF-κB/caspase signaling pathway. Open Life Sci 2020;15:696-710. [PMID: 33817258 DOI: 10.1515/biol-2020-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Zhu GQ, Huang S, Huang GQ, Wang LR, Lin YQ, Wu YM, Shi KQ, Wang JT, Zhou ZR, Braddock M, Chen YP, Zhou MT, Zheng MH. Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. Oncotarget 2015;6:24533-49. [PMID: 26109432 DOI: 10.18632/oncotarget.4528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
34 You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Reference Citation Analysis]
35 Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, Matsuzaki Y, Ohira H, Yoshiji H, Takikawa H; Japan PBC Study Group (JPBCSG). Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol. 2018;53:1151-1158. [PMID: 29663077 DOI: 10.1007/s00535-018-1465-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
36 Virani S, Akers A, Stephenson K, Smith S, Kennedy L, Alpini G, Francis H. Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma. J Liver 2018;7:231. [PMID: 30613437 DOI: 10.4172/2167-0889.1000231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
37 Madir A, Božin T, Mikolašević I, Milić S, Štimac D, Mijić M, Filipec Kanižaj T, Biloglav Z, Lucijanić M, Lucijanić I, Grgurević I. Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study. Croat Med J 2019;60:494-502. [PMID: 31894914 [PMID: 31894914 DOI: 10.3325/cmj.2019.60.494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
38 Richardson N, Ng STH, Wraith DC. Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases. Front Immunol 2020;11:1586. [PMID: 32793226 DOI: 10.3389/fimmu.2020.01586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
39 Sathe AG, Tuite P, Chen C, Ma Y, Chen W, Cloyd J, Low WC, Steer CJ, Lee BY, Zhu XH, Coles LD. Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. J Clin Pharmacol 2020;60:744-50. [PMID: 32052462 DOI: 10.1002/jcph.1575] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]